Clinical Trial: Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa

U.S., Feb. 22 -- ClinicalTrials.gov registry received information related to the study (NCT06840392) titled 'Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa' on Feb. 17.

Brief Summary: The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).

Study Start Date: March 12

Study Type: INTERVENTIONAL

Condition: Hidradenitis Suppurativa

Intervention: DRUG: Remibrutinib Dose A

Remibrutinib Dose A (oral)

DRUG: Remibrutinib Dose B

Remibrutinib Dose B (oral)

DRUG: Placebo 1

Placebo matching to remibrut...